Stock Ratings / Health Care / GSK / financials

SNY (59) REGN (80) BMY (63) VRTX (80) ⌘ Pro Terminal →

GSK plc American (GSK) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$49.51 +1.71% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $49.57

GSK plc American (GSK) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $98.47B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GSK Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GSK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, GSK plc American (NYSE: GSK) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $49.51 (+1.71% 1D, market cap $98.47B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, GSK ranks #205 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GSK compare to SNY and REGN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GSK carries a Roarable D+ (57/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, SNY (Sanofi ADS) holds a C- grade (59/100 RQD, P/E 32.8x, ROIC 9.9%, cap $105.19B) and REGN (Regeneron Pharmaceuticals Inc.) posts a B+ grade (80/100 RQD, P/E 18.7x, ROIC 9.4%, cap $84.30B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GSK?

▼

For GSK plc American (GSK), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #205 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $49.57 (+0.12%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 15.8% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-0.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GSK)Realized 20D OHLCV Swing Band: ±3.7%

Deterministic 5-Pillar Attribution (57/100 Composite)

🔍 WHY GSK SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (28% of score)

Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (21% of score)

SEC XBRL Trailing 12 Months: 15.8% FCF Margin ($2.18B FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$46.27+9.4% Next Q

Q2 (-2Q)

Grade C-$50.63+0.6% Next Q

Q3 (-1Q)

Grade C-$50.94-2.8% Next Q

Current

Grade D+$49.51-0.2% Hist 90D α

Trajectory: D (49) → D+ (57)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the GSK Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, GSK faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($49.30) or 200D SMA ($52.34) invalidates the momentum regime and cuts Target Base ($49.29) toward Bear Floor ($38.45).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GSK• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GSK Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 57%NO 43%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How GSK Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$2.18B (15.8% FCF Margin)

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GSK)

✓Walkthrough of GSK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GSK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.73%▼ DESCENDING CHANNEL

2026-11-02O $48.74H $49.51L $48.68C $49.51VOL 5.61M

RES: $50.87SUP: $44.48SMA50: $49.30SMA200: $52.34

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GSK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GSK Butterfly Map → + Track GSK →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.3%/yr Implied 5Y Growth

vs. +8.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GSK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GSK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GSK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GSK)

Health Care Rank #205 of 1016 ⚔️ SNY vs GSK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GSK vs. SNY, REGN, BMY, VRTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, GSK plc American (GSK) ranks #205 by composite RQD confidence (57/100, grade D+) and #24 by equity capitalization ($98.47B). Within this direct 5-issuer industry benchmark cohort, BMY leads on earnings valuation at 17.8x trailing P/E, while VRTX leads on capital efficiency and profitability with 20.0% ROIC and 86.2% gross margin. REGN currently holds the highest overall quantitative score in the immediate peer group at 80/100 (B+) compared with GSK at 57/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GSK ACTIVE GSK plc American	D+	57/100	32.8x	—	9.9%	+1.71%	$98.47B	Benchmark Subject
SNY Sanofi ADS	C-	59/100	32.8x	—	9.9%	+2.81%	$105.19B	/sny-vs-gsk →
REGN Regeneron Pharmaceuticals Inc.	B+	80/100	18.7x	—	9.4%	+13.33%	$84.30B	/regn-vs-gsk →
BMY Bristol-Myers Squibb Company	C	63/100	17.8x	71.1%	13.3%	+1.78%	$125.40B	/bmy-vs-gsk →
VRTX Vertex Pharmaceuticals Incorporated	B+	80/100	34.6x	86.2%	20.0%	+3.50%	$136.87B	/vrtx-vs-gsk →

2. GSK Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

GSK plc American (GSK) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $98.47B, trailing P/E of 32.8x, forward P/E of 30.5x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.

3. GSK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GSK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does GSK compare to SNY and REGN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for GSK?

Where is GSK trading relative to its 50-day, 200-day, and 52-week technical levels?

GSK last traded at $49.51 (+1.71% on volume of 4,767,316 shares), positioning the stock +0.43% above its 50-day simple moving average ($49.30) and -5.41% below its 200-day simple moving average ($52.34). Across its 52-week range of $45.81 to $61.70, GSK sits at the 23.3% percentile with a 14-day RSI of 46.8 (NEUTRAL RANGE) and an implied next-earnings move of ±3.7% ($47.68 to $51.34).

GSK Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is GSK plc American (GSK)?

In Trailing 12 Months, GSK converted $13.8B of revenue into a 52% gross margin, 13.9% operating margin, and $2.2B in free cash flow (15.8% FCF margin).

Direct Sub-Reports: GSK RQD Cockpit GSK 12M Forecast GSK Earnings & Move GSK Dividends & DRIP GSK Insiders & 13F GSK Whale Options GSK Profit Sankey GSK News & Why

ROARABLE RATING BRIEF • RQD 57/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

GSK — GSK plc American: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:08:14Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, GSK scores 57 out of 100, a D+ grade labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:

Fundamental Cash Engine: 12 / 20. The rating cites ROIC of 9.9% and an FCF yield of 2.21%. For a prospective investor, this suggests the business earns a modest return on invested capital and that the cash generated relative to the share price is thin. The valuation therefore leans heavily on future earnings growth rather than current cash returns.
Whale 13F Flow: 8 / 20. The pillar is scored on institutional accumulation and options positioning. Its low score indicates limited evidence of sustained large-holder accumulation in the source data.
Insider Conviction: 12 / 20. Scored on SEC Form 4 and Congressional PTR cluster flow. The moderate score reflects insider activity that is not strongly one-directional in the rating's inputs.
Macro Regime Fit: 9 / 20. Beta is 0.95 and the rating notes sector sensitivity. A beta near 1 implies the stock moves roughly in line with the broad market, and this pillar's low score suggests the current macro backdrop is not especially supportive for this profile.
Forensic Balance Sheet: 16 / 20. This is the strongest pillar, supported by an Altman Z-Score of 3.74, a Piotroski F-Score of 8/9, and Debt/Equity of 0.39. Balance-sheet quality is a relative strength and reduces solvency concern.

Implications: The upside case rests on earnings durability and balance-sheet strength. The valuation tradeoff is significant: at a P/E (TTM) of 32.8 and forward P/E of 30.5, the stock is priced at a premium relative to its modest FCF yield, so returns depend on execution. The rating's overall verdict reflects weak cash-return and flow signals against a solid balance sheet.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
48.68	$98.47B	32.8	30.5	21	1.48	0%	0.95	$45.81 - $61.7	9.9%

Business

GSK plc American is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the company profile. Its market capitalization is $98.5B. The source data does not detail its products, customers, or revenue model. Per the profile, it trades on the NYSE under the ticker GSK.

Recent Catalysts & News Wire Analysis

The news wire contains one item: a Kalkine Media report, dated 1h ago per the feed, headlined around directors and PDMRs completing share acquisitions via dividend reinvestment on 8-9 October 2026. Its light indicator is YELLOW and impact label is MARKET WIRE. The summary is generic and does not specify the size or significance of the transactions. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are present. Key watch items from the available data are the 52-week range ($45.81 - $61.7) relative to the current price and the stock's modest daily move (-0.12%).

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is NONE and there are no butterfly links. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are not available in source data.

Open Questions

What are GSK's reported revenue, operating income, net income, EPS, FCF, cash, and debt by period? The financials section is empty.
What is the analyst consensus rating and price target range? No analyst data was provided.
Who are the major institutional and insider holders, and what are their recent 13F, Form 4, or Congressional trades? The holders section is empty.
What drives the 0% gross margin figure reported in the market data, and is it a data-classification issue or an accounting presentation?
What is the size and direction of the insider share acquisitions referenced in the news wire, relative to total shares outstanding?

GSK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for GSK plc American (GSK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GSK Debate Forum (3) ↓

🟡 MARKET WIRE Kalkine Media • 7h ago

GSK plc (GSK) Directors and PDMRs Complete Share Acquisitions via Dividend Reinvestment on 8-9 October 2026

Kalkine Media report covering GSK plc American (GSK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 8h ago

Alfasigma Announces New Linerixibat Data Across PBC and Liver Disease to be Presented at AASLD’s The Liver Meeting 2026

Five presentations will highlight new analyses of linerixibat in cholestatic pruritus associated with primary biliary cholangitis, including an oral presentation and four posters from the Phase 3 GLISTEN study and real-w

Read Full Source ↗

🟢 CATALYST Yahoo • 1d ago

GSK (LSE:GSK) Wins FDA Nod For Jemperli As ESMO Data Builds Oncology Case

GSK (LSE:GSK) received accelerated FDA approval for Jemperli as the first immunotherapy for certain rectal cancer patients. The approval covers a genetically defined group of rectal cancer cases where Jemperli offers a n

Read Full Source ↗

🟢 CATALYST SeekingAlpha • 3d ago

Gilead Sciences: Why I Remain Bullish After Q3

Gilead Sciences had a strong Q3, while successfully shifting its R&D focus from HIV to the immunology market. Read why GILD stock is a buy.

Read Full Source ↗

🔴 RISK WATCH SeekingAlpha • 3d ago

GSK: The Gas Pedal Is Still Down, But Bumps Ahead

GSK stock remains a Buy despite Q3 misses, with Specialty Medicines growth, pipeline momentum, valuation upside, and key risks to watch. See more here.

Read Full Source ↗

🔴 RISK WATCH Benzinga • 4d ago

Jefferies Downgrades GSK to Hold, Lowers Price Target to $55.9

Jefferies analyst Michael Leuchten downgrades GSK (NYSE:GSK) from Buy to Hold and lowers the price target from $67.4 to $55.9.

Read Full Source ↗

🟢 CATALYST Yahoo • 4d ago

GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?

GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 4d ago

Chiesi Group appoints Paolo Paoletti to its Board of Directors

PARMA, Italy, October 29, 2026--Chiesi, the international research-focused biopharmaceutical group, today announced the appointment of Paolo Paoletti, M.D. to its Board of Directors, effective as of today. Paoletti is an

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GSK Bull vs. Bear Conversation Board — What's Your Call at $49.51?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GSK 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $52.57 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is GSK (D+ • RQD 57/100) a Buy at $48.68?

Welcome to the GSK (GSK plc American) Roar Pit. Current RQD Composite is 57/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.8x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $37.00 (-24.0%)

Spot @ $48.68

Pump the brakes on GSK — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on GSK, but look at what you are paying: 32.8x trailing P/E with tightening sector spreads. Unless GSK plc American expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $56.96 (+17.0%)

Spot @ $48.68

GSK cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on GSK, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $48.68 (52-wk range $45.81 - $61.70), any beat on forward guidance forces shorts and underweight funds to chase.